Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,293
  • Shares Outstanding, K 13,797
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,200 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.13

Options Overview Details

View History
  • Implied Volatility 296.52% ( +108.76%)
  • Historical Volatility 73.90%
  • IV Percentile 87%
  • IV Rank 66.42%
  • IV High 425.72% on 04/26/24
  • IV Low 41.03% on 09/27/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 427
  • Volume Avg (30-Day) 559
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 20,655
  • Open Int (30-Day) 19,855

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +65.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +1.63%
on 12/20/24
7.52 -41.89%
on 11/25/24
-2.17 (-33.18%)
since 11/20/24
3-Month
4.30 +1.63%
on 12/20/24
10.54 -58.54%
on 10/28/24
-4.10 (-48.41%)
since 09/20/24
52-Week
4.30 +1.63%
on 12/20/24
22.49 -80.57%
on 12/27/23
-6.38 (-59.35%)
since 12/20/23

Most Recent Stories

More News
Annovis Bio (NYSE: ANVS) Eyes Clear Path Forward for Buntanetap

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s (“AD”) and Parkinson’s (“PD”)....

ANVS : 4.37 (-0.68%)
Annovis Bio (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Investor Webcast

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders...

ANVS : 4.37 (-0.68%)
Annovis Bio (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace

Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder,...

ANVS : 4.37 (-0.68%)
Annovis Bio (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative Diseases

Annovis Bio (NYSE: ANVS) was featured in an interview with Today’s Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director...

ANVS : 4.37 (-0.68%)
Annovis Bio (NYSE: ANVS) to Present Recent Achievements, Strategic Outlook During Investor Webcast

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 4.37 (-0.68%)
Annovis Bio (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates

Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria...

ANVS : 4.37 (-0.68%)
Annovis Bio, Inc. Announces Live Investor Webcast for December 11, 2024, to Discuss Clinical Progress and Strategic Initiatives

Annovis Bio will host an investor webcast on December 11, 2024, discussing clinical progress and strategic initiatives.Quiver AI SummaryAnnovis Bio, Inc., a clinical-stage company focused on therapies...

ANVS : 4.37 (-0.68%)
Annovis to Host Year-End Investor Webcast on December 11, 2024

ANVS : 4.37 (-0.68%)
Annovis Bio (NYSE: ANVS) Paving the Way for NDA Submission

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s...

ANVS : 4.37 (-0.68%)
Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 4.37 (-0.68%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 4.73
2nd Resistance Point 4.63
1st Resistance Point 4.50
Last Price 4.37
1st Support Level 4.27
2nd Support Level 4.17
3rd Support Level 4.04

See More

52-Week High 22.49
Fibonacci 61.8% 15.54
Fibonacci 50% 13.40
Fibonacci 38.2% 11.25
Last Price 4.37
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar